689 related articles for article (PubMed ID: 31397685)
1. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
3. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
[TBL] [Abstract][Full Text] [Related]
4. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
5. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
11. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
13. Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4.
John K; Franck M; Al Aoua S; Rau M; Huber Y; Schattenberg JM; Geier A; Bahr MJ; Wedemeyer H; Schulze-Osthoff K; Bantel H
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35956017
[TBL] [Abstract][Full Text] [Related]
14. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
Chan WK; Nik Mustapha NR; Mahadeva S
Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
[TBL] [Abstract][Full Text] [Related]
15. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
16. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
Mueller S; Nahon P; Rausch V; Peccerella T; Silva I; Yagmur E; Straub BK; Lackner C; Seitz HK; Rufat P; Sutton A; Bantel H; Longerich T
Hepatology; 2017 Jul; 66(1):96-107. PubMed ID: 28170108
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH
PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
20. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
